drugset / Trial / NCT07539090

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

NCT07539090

Phase 1 Recruiting 24 enrolled Deciphera Pharmaceuticals, LLC
NaSequentialOpen-labelBasic science

Summary

The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of combined oral contraceptive (COC) (ethinyl estradiol/levonorgestrel) in healthy female participants. This study will last approximately 35 days.

Timeline

Start
2026-06-05
Primary completion
2026-08
Completion
2026-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Levonorgestrel Small molecule Oral
Subject Vimseltinib Small molecule Oral
Subject ethinyl estradiol Small molecule Oral

Indications

No indication recorded.